Celestial Therapeutics Accepted into the Prestigious StartX Med Accelerator Program
Image courtesy of StartX
Celestial Therapeutics Inc. (“Celestial”) is pleased to announce that it has been accepted into the StartX community of 1,800+ Stanford Alumni and Professor founders for the Summer 2021 cohort. Located in the heart of Silicon Valley, StartX is one of the most prominent technology accelerators in the world, historically accepting only the top 8% of Stanford affiliated applicant companies. After 10 years of activity, the combined market cap of StartX’s alumni is $30B+ with 80 acquisitions and a 92% VC success rate.
Through acceptance into this program, Celestial will be able to leverage the following StartX resources to advance their lead dual modal antiviral inhalation product, CT-02, into human clinical trials and to support Celestial’s business plan:
Access to the StartX investment community to tap into the investor network to raise funds;
Opportunities to recruit world class scientific personnel who are members of the StartX community;
Guidance from StartX mentors, a prestigious group of investors, proven entrepreneurs and the thought leaders comprising Stanford’s world-renowned faculty; and
Availability of resources from StartX affiliate partners, including leading providers of banking, web services, human resources, legal, accounting and other key operational partners.
Inclusion in the StartX community is a significant achievement for Celestial. This development will accelerate Celestial’s near-term growth in measurable and meaningful ways and represents a major milestone in the growth of the company.
About Celestial Therapeutics
Celestial Therapeutics is a start-up California based biotechnology company developing a new class of dual-modal anti-infective and anti-inflammatory drugs for conditions which currently lack safe and effective treatments. Celestial’s lead product, CT-02, is being developed as a first-ever broad spectrum dual-modal antiviral & anti-inflammatory inhalation therapeutic for treating lung infections due to Respiratory Syncytial Virus (RSV), Influenza Virus (IV), and Rhinoviruses (RV). Celestial’s new class of pulmonary surfactant lipid and protein drugs are broad-spectrum for treating infections including bacterial, viral, yeast, fungal, and mycobacterial infections, while also acting as safe and effective anti inflammatories. Celestial’s treatments have the potential to overcome drug resistance and to provide novel therapies for pandemic flu.
About StartX
StartX is a nonprofit organization advancing the development of Stanford’s top entrepreneurs through experiential education, access to thousands of VCs and investors, and a Who’s Who of industry leaders and serial entrepreneurs providing mentorship. The founder community consists of a diverse mix of 1,800+ well funded Growth-Stage Founders, tenured Stanford Professor Founders, and highly-successful Stanford Alumni Founders. Collectively, StartX companies have raised $8 billion in funding with a combined valuation of more than $30 billion to date. StartX’s Corporate Innovation program helps global corporations quickly test market-ready technology from Stanford alumni founders through structured co-creation and pilot programs. Ranked as a number one accelerator nationally by MIT’s Seed Accelerator Rankings Project, StartX venture funded companies have a 92% survival and acquisition rate in a wide range of industries from consumer Internet and retail products to enterprise software, biotechnology and medical devices.
StartX and StartX Med, the medical entrepreneurial vertical of StartX, includes accomplished founders ranging from undergraduates and masters students to post docs, professors and Stanford alumni being mentored by top Silicon Valley industry leaders. For medical tech founders homegrown at Stanford’s School of Medicine, having intimate access to domain experts and care environments has been fundamental to their success. StartX Med entrepreneurial scientists are changing the world with medical breakthroughs and successful life-saving research trials, including an average of more than six FDA approvals per year. Clinical partners of StartX Med companies encompass more than 250 hospitals, 30,000 care centers, 50,000 physicians and 65 million annual patient visits. StartX Med founders also have the opportunity to utilize 2,000 square feet of shared wet lab space at the StartX facility, located down the street from Stanford University. The StartX Med COVID-19 Task Force, mobilized at the onset of the pandemic, consists of more than 150 Stanford University alumni scientists, physicians, professors, and engineers delivering critical solutions for the prevention, diagnostics, and treatment of the novel coronavirus.
StartX continues to be a unique startup community compared to accelerators and incubators and does not take equity in companies for admittance into its programs. Please follow us on Twitter @StartX.